Calcium fructoborate and knee discomfort
Self-rated pain and daily function in calcium fructoborate studies.
Key points
- In adults with self-reported knee discomfort, calcium fructoborate reduced self-rated pain and discomfort over two weeks compared with placebo. This is a preliminary signal of less discomfort for the compound studied. [1] See the evidence 1 2
- In a separate study, adults with knee discomfort reported improved daily function with the studied calcium fructoborate regimens. This is a preliminary indication of possible easing of everyday activities. [2] See the evidence 1
Practical guide
Check the conclusions and whether they apply to your situation.
Pain and daily function were assessed separately in adults with knee discomfort.
Key points
Why these conclusions
Discomfort studies
Adults with self-reported knee discomfort received 110 mg calcium fructoborate complex twice daily or placebo for 14 days. Two pain and discomfort ratings decreased more with the compound studied. [1]
A separate 90-day study used 216 mg calcium fructoborate in the morning or 108 mg twice daily. In an additional analysis, participants reported improved daily function from day 30 compared with placebo. [2]
The specification of the calcium fructoborate material assessed by EFSA is 2.5–2.9% boron, typically 2.7%; compound mass differs from elemental mass. These percentages cannot automatically be transferred to another product. [3]
After two weeks, the total WOMAC knee pain, stiffness and function score fell 13.73 points more than with placebo.
| Parameter | Data |
|---|---|
| Result | After two weeks, the total WOMAC knee pain, stiffness and function score fell 13.73 points more than with placebo. Difference in WOMAC change at day 14 −13.73 points (95% CI −19.28…−8.19) between calcium fructoborate and placebo; at day 7 −5.30 (95% CI −10.84…0.24), p=0.061. |
| Participants | 60 adults with self-reported knee discomfort |
| Form | Calcium fructoborate |
| Dose | 110 mg of complex twice daily |
| Dose basis | 110 mg of complex twice daily |
| Comparator | Placebo |
| Duration | 14 days |
| Confidence | 2/4: Precision: small sample; for several outcomes, the between-group effect size and CI are unavailable in the accessible package.; Consistency: one relevant trial per outcome; reproducibility not assessed.; Applicability to the specified group: limited to the stated population, form, dose and duration; do not transfer to other groups and products.; Possible publication bias: undetermined with a single study.; Study methods: limited assessment: a full independent RoB 2 was not performed; some allocation, selective reporting and attrition methods are unknown. Commercial ties and retrospective registration were disclosed for the knee study. |
| Evidence base | 1 trial |
| Sources | [1] |
After two weeks, the McGill pain score fell 8.9 points more than with placebo.
| Parameter | Data |
|---|---|
| Result | After two weeks, the McGill pain score fell 8.9 points more than with placebo. Difference in change at day 14 −8.9 points, 95% CI −12.32…−5.48; at day 7 −5.8 points, p=0.0009. |
| Participants | 60 adults with self-reported knee discomfort |
| Form | Calcium fructoborate |
| Dose | 110 mg calcium fructoborate twice daily, compound mass |
| Dose basis | 110 mg calcium fructoborate twice daily, compound mass |
| Comparator | Placebo |
| Duration | 14 days |
| Confidence | 2/4: Precision: serious limitation: 60 participants; the confidence interval excludes zero, but a threshold of meaningful benefit and its persistence in this group are not established.; Consistency: one suitable independent trial; consistency cannot be assessed, which alone is not grounds for downgrading.; Applicability: directly concerns the specified group, intervention and outcome; no transfer beyond them is intended.; Possible publication bias: insufficient data to establish publication bias in one small evidence base; no separate downgrade.; Study methods: serious limitation: commercial and patent interests, retrospective registration, unclear allocation concealment and subjective assessment. |
| Evidence base | 1 trial |
| Sources | [1] |
In an additional analysis, participants reported improved daily function from day 30 compared with placebo.
| Parameter | Data |
|---|---|
| Result | In an additional analysis, participants reported improved daily function from day 30 compared with placebo. Both active regimens differed from placebo in self-rated daily function from day 30. The published abstract did not provide the numerical between-group difference or confidence interval. |
| Participants | 121 adults with self-reported knee discomfort: 40 on placebo, 40 taking 216 mg calcium fructoborate in the morning and 41 taking 108 mg twice daily |
| Form | Calcium fructoborate |
| Dose | 216 mg calcium fructoborate in the morning or 108 mg twice daily, compound mass |
| Dose basis | 216 mg calcium fructoborate in the morning or 108 mg twice daily, compound mass |
| Comparator | Placebo; the once-daily group also received an evening placebo |
| Duration | 90 days; additional analysis from day 30 |
| Confidence | 1/4: Precision: serious limitation: no usable between-group contrast or confidence interval; magnitude and clinical importance are unknown.; Consistency: one suitable independent trial; consistency cannot be assessed, which alone is not grounds for downgrading.; Applicability: directly concerns self-rated daily activity in the studied adults, not objective mobility or the 14-day trial result.; Possible publication bias: insufficient data to establish publication bias in one small evidence base; no separate downgrade.; Study methods: very serious limitation: a sponsor-linked additional exploratory analysis of many scales, items, regimens and time points is not a prespecified confirmatory result. |
| Evidence base | 1 trial |
| Sources | [2] |
The specification of the calcium fructoborate material assessed by EFSA is 2.5–2.9% boron, typically 2.7%; compound mass differs from elemental mass. These percentages cannot automatically be transferred to another product.
The specification of the calcium fructoborate material assessed by EFSA is 2.5–2.9% boron, typically 2.7%; compound mass differs from elemental mass. These percentages cannot automatically be transferred to another product. [3]
Sources
- Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. https://pmc.ncbi.nlm.nih.gov/articles/PMC4051624/
- Impact of Calcium Fructoborate on WOMAC and McGill Subscales and Individual WOMAC Questions: Post-Hoc Analyses of Data from a Previously Published 90-Day Randomized Clinical Trial. https://scholarpublishing.org/journals/index.php/EJAS/article/view/8457
- Safety of calcium fructoborate as a novel food. https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2021.6661
Methodology: Subpages evidence-led supplement pipeline v1